Literature DB >> 11841430

Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission.

Giovanni F Torelli1, Anna Guarini, Gabriella Palmieri, Massimo Breccia, Antonella Vitale, Angela Santoni, Robin Foa.   

Abstract

New therapeutic approaches are needed to improve the cure rates in acute myeloid leukaemia (AML). The present study was designed to investigate whether: (1) cytotoxic lymphocytes could be expanded from AML patients in complete remission; (2) their signal transduction machinery was preserved; (3) these cells were capable of producing cytokines involved in the cytolytic process; and (4) these cells showed cytotoxic activity against allogeneic and autologous blasts. By co-culturing blood mononuclear cells with feeder cells, we obtained an average 5.3-fold increase in the total cell number and a 35-fold increase in natural killer (NK) cells. Expression of the zeta chain and of tyrosine kinases of the Src and Syk-ZAP families involved in the triggering of NK functions was analysed on expanded cells. The results demonstrated a signal transduction apparatus preserved and quantitatively similar to that of normal donors. After phorbol myristate acetate and ionomicin stimulation, the ability of expanded cells to produce interferon gamma and tumour necrosis factor alpha was documented. Patients' expanded cells showed a cytotoxic activity against target lines and allogeneic blasts which was similar to that of normal donors. Purification experiments indicated that the NK cell fraction was responsible for most of the lytic effect. More significantly, these cells also exerted a lytic effect against autologous blasts that could be further enhanced following incubation with low-dose interleukin 2. These findings document the possibility of expanding cytotoxic effectors with preserved signal transduction machinery and autologous killing capacity from AML patients in remission, and suggest a new potential immunotherapeutic strategy for the management of early disease recurrence or of residual disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841430

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.

Authors:  Martha Luevano; Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

2.  Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.

Authors:  Kathryn Hall; Karen J Scott; Ailsa Rose; Michael Desborough; Kevin Harrington; Hardev Pandha; Christopher Parrish; Richard Vile; Matt Coffey; David Bowen; Fiona Errington-Mais; Alan A Melcher
Journal:  Biores Open Access       Date:  2012-01

3.  Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.

Authors:  Cecele J Denman; Vladimir V Senyukov; Srinivas S Somanchi; Prasad V Phatarpekar; Lisa M Kopp; Jennifer L Johnson; Harjeet Singh; Lenka Hurton; Sourindra N Maiti; M Helen Huls; Richard E Champlin; Laurence J N Cooper; Dean A Lee
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

4.  Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.

Authors:  Louise M E Müller; Matthew Holmes; Joanne L Michael; Gina B Scott; Emma J West; Karen J Scott; Christopher Parrish; Kathryn Hall; Sina Stäble; Victoria A Jennings; Matthew Cullen; Stewart McConnell; Catherine Langton; Emma L Tidswell; Darren Shafren; Adel Samson; Kevin J Harrington; Hardev Pandha; Christy Ralph; Richard J Kelly; Gordon Cook; Alan A Melcher; Fiona Errington-Mais
Journal:  J Immunother Cancer       Date:  2019-07-01       Impact factor: 13.751

Review 5.  Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.

Authors:  Mattias Carlsten; Marcus Järås
Journal:  Front Immunol       Date:  2019-10-11       Impact factor: 7.561

Review 6.  A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies.

Authors:  Veronica Ramos-Mejia; Jose Arellano-Galindo; Juan Manuel Mejía-Arangure; Mario Ernesto Cruz-Munoz
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

Review 7.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.

Authors:  Carin I M Dahlberg; Dhifaf Sarhan; Michael Chrobok; Adil D Duru; Evren Alici
Journal:  Front Immunol       Date:  2015-11-30       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.